<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public">
	<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>110th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 1359</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20070510">May 10, 2007</action-date>
			<action-desc><sponsor name-id="S229">Mrs. Murray</sponsor> (for
			 herself, <cosponsor name-id="S231">Mr. Bennett</cosponsor>,
			 <cosponsor name-id="S307">Mr. Brown</cosponsor>, and <cosponsor name-id="S213">Mr. Akaka</cosponsor>) introduced the following bill; which was
			 read twice and referred to the <committee-name committee-id="SSHR00">Committee
			 on Health, Education, Labor, and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act to enhance public
		  and health professional awareness and understanding of lupus and to strengthen
		  the Nation’s research efforts to identify the causes and cure of
		  lupus.</official-title>
	</form>
	<legis-body>
		<section commented="no" display-inline="no-display-inline" id="HC4E1742433924DB9ACF3E53095FB500" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Lupus Research, Education, Awareness,
			 Communication, and Healthcare Amendments of 2007</short-title></quote>.</text>
		</section><section commented="no" display-inline="no-display-inline" id="H0852E6D155CE407886E78CECB3B67165" section-type="subsequent-section"><enum>2.</enum><header>Table of
			 contents</header><text display-inline="no-display-inline">The table of contents
			 for this Act is as follows:</text>
			<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration">
				<toc-entry idref="HC4E1742433924DB9ACF3E53095FB500" level="section">Sec. 1. Short title.</toc-entry>
				<toc-entry idref="H0852E6D155CE407886E78CECB3B67165" level="section">Sec. 2. Table of contents.</toc-entry>
				<toc-entry idref="H11CDBDC645FC494D87EFE367947CC3D2" level="section">Sec. 3. Findings.</toc-entry>
				<toc-entry idref="HAEBF8EBFE4F84835B79DDC6B37A94FA0" level="title">Title I—Expanding and Improving Research on Lupus</toc-entry>
				<toc-entry idref="HE9AC03C5DDA34C54B3FD0094129137E3" level="section">Sec. 101. Expansion of lupus biomedical research.</toc-entry>
				<toc-entry idref="H2FF596926DCC4EB3BA4400BB9E3849B0" level="section">Sec. 102. Strengthening lupus epidemiology; lupus
				study.</toc-entry>
				<toc-entry idref="HBD1F4C336A8F4EF89D112070F6B85BD" level="title">Title II—Enhancing lupus awareness and education</toc-entry>
				<toc-entry idref="H33D7BFC98342468C8052DC05DC2FBE86" level="section">Sec. 201. Increasing public awareness and improving health
				professional education.</toc-entry>
			</toc>
		</section><section commented="no" display-inline="no-display-inline" id="H11CDBDC645FC494D87EFE367947CC3D2" section-type="subsequent-section"><enum>3.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following
			 findings:</text>
			<paragraph commented="no" display-inline="no-display-inline" id="HD0E45ABDC9B1492CA8FAD7016B397B48"><enum>(1)</enum><text display-inline="yes-display-inline">Lupus is a serious, complex, debilitating
			 autoimmune disease that can cause inflammation and tissue damage to virtually
			 any organ system in the body, including the skin, joints, other connective
			 tissue, blood and blood vessels, heart, lungs, kidney, and brain.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H5B2749298F1640D5B84D2F69351B4E4E"><enum>(2)</enum><text display-inline="yes-display-inline">The Lupus Foundation of America, Inc.
			 estimates that approximately 1,500,000 to 2,000,000 Americans live with some
			 form of lupus; lupus affects women 9 times more often than men and 80 percent
			 of newly diagnosed cases of lupus develop among women of child-bearing
			 age.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HC11A81BB0D2A4857A5A5F7EE0007971E"><enum>(3)</enum><text display-inline="yes-display-inline">Lupus disproportionately affects women of
			 color; it is 2 to 3 times more common among African-Americans, Hispanics,
			 Asians, and Native Americans and is generally more prevalent in minority
			 populations, a health disparity that remains unexplained. According to the
			 Centers for Disease Control and Prevention, the rate of lupus mortality has
			 increased since the late 1970s and is higher among older African-American
			 women.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H698238DD0E064EA1BEF00060331F8089"><enum>(4)</enum><text display-inline="yes-display-inline">There have been no new drugs approved by
			 the Food and Drug Administration specifically for lupus in nearly 40 years and
			 while current treatments for the disease can be effective, they can lead to
			 damaging side effects.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H467A19C54EE9460EBCA581D04FC0F4C8"><enum>(5)</enum><text display-inline="yes-display-inline">The pain and fatigue associated with lupus
			 can threaten people’s ability to live independently and make it difficult to
			 maintain employment and lead normal lives. One in 5 people with lupus is
			 disabled by the disease, and consequently receives support from government
			 programs, including medicare, medicaid, social security disability, and social
			 security supplemental income.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HBA9399A7A472451BBC907ECEB84365F"><enum>(6)</enum><text display-inline="yes-display-inline">The estimated average annual cost of
			 medical treatment for an individual with lupus can range between $10,000 and
			 $30,000; for people who have the most serious form of lupus, medical costs can
			 greatly exceed this amount, causing a significant economic, emotional, and
			 social burden to the entire family and to society.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H2502D607B62F40D2BEC513C474597874"><enum>(7)</enum><text display-inline="yes-display-inline">More than <fraction>1/2</fraction> of the
			 people with lupus suffer 4 or more years and visit 3 or more physicians before
			 obtaining a diagnosis of lupus; early diagnosis of, and commencement of
			 treatment for, lupus can prevent or reduce serious organ damage, disability,
			 and death.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7954F8061989407DAD5C7EE7A76C77C3"><enum>(8)</enum><text display-inline="yes-display-inline">Despite the magnitude of lupus and its
			 impact on individuals and families, health professional and public
			 understanding of lupus remains low; only 1 of 5 Americans can provide even
			 basic information about lupus, and awareness of lupus is lowest among adults
			 ages 18 to 34, the age group most likely to develop symptoms of lupus.</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H76A3E6A5DFD348F700E61FE813051C2D"><enum>(9)</enum><text display-inline="yes-display-inline">Lupus is a significant national health
			 issue that deserves a comprehensive and coordinated response by Federal and
			 State governments with the involvement of the healthcare provider, patient, and
			 public health communities.</text>
			</paragraph></section><title commented="no" id="HAEBF8EBFE4F84835B79DDC6B37A94FA0" style="OLC"><enum>I</enum><header>Expanding and Improving Research on
			 Lupus</header>
			<section commented="no" display-inline="no-display-inline" id="HE9AC03C5DDA34C54B3FD0094129137E3" section-type="subsequent-section"><enum>101.</enum><header>Expansion of lupus
			 biomedical research</header><text display-inline="no-display-inline">Section
			 441A of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/285d-6a">42 U.S.C. 285d–6a</external-xref>) is amended to
			 read as follows:</text>
				<quoted-block act-name="" display-inline="no-display-inline" id="HD3F4B20157CD44B7962800E7F6F2B1E4" style="traditional">
					<section commented="no" display-inline="no-display-inline" id="H42E8949ABBD14E07A011623951B846FD" section-type="subsequent-section"><enum>441A.</enum><header>Expansion of lupus biomedical research</header><subsection commented="no" display-inline="yes-display-inline" id="H10EE15E5E6D440D4A16CD646CBF42E68"><enum>(a)</enum><header>In
				general</header><text display-inline="yes-display-inline">The Secretary, acting
				through the Director of the Institute, shall expand and intensify research and
				related activities of the Institute with respect to lupus.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="HF3FB63F09F884D4D974335452C890378"><enum>(b)</enum><header>Coordination
				with other institutes</header><text display-inline="yes-display-inline">The
				Director of the Institute shall coordinate the activities of the Director under
				subsection (a) with similar activities conducted by the other national research
				institutes and agencies of the National Institutes of Health to the extent that
				such institutes and agencies have responsibilities that are related to
				lupus.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="H0E6A3287BEB14F18911F6500C3F9AB25"><enum>(c)</enum><header>Programs for
				lupus</header><text display-inline="yes-display-inline">In carrying out
				subsection (a), the Director of the Institute shall conduct or support research
				to expand the understanding of the causes of, and to find a cure for, lupus.
				Activities under such subsection shall include conducting and supporting the
				following:</text>
							<paragraph commented="no" display-inline="no-display-inline" id="H8C03243C0190461D95F47D365BDE4809"><enum>(1)</enum><text display-inline="yes-display-inline">Basic research to discover the pathogenesis
				and pathophysiology of the disease.</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H1E733F131BB34AE799039E8D6549CD96"><enum>(2)</enum><text display-inline="yes-display-inline">Research to determine the reasons
				underlying the disproportionate prevalence of lupus in African-American,
				Hispanic, Native American, and Asian women.</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H77E5E1D9E3514DAEB940AF46517BA46C"><enum>(3)</enum><text display-inline="yes-display-inline">Epidemiological studies to address the
				frequency and natural history of the disease and the differences between the
				sexes and among racial and ethnic groups with respect to the disease.</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H91DEC3C2C52A4BA6BBF400EB003107AF"><enum>(4)</enum><text display-inline="yes-display-inline">Clinical research for the development and
				evaluation of new treatments, including new biological agents.</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H246CD7D4E27E4776B8993373A3ECF2D4"><enum>(5)</enum><text display-inline="yes-display-inline">Research to validate lupus
				biomarkers.</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HC28CE5F045F34F62B4BA2F7925C972E8"><enum>(6)</enum><text display-inline="yes-display-inline">Research to develop improved diagnostic
				tests.</text>
							</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section><section commented="no" display-inline="no-display-inline" id="H2FF596926DCC4EB3BA4400BB9E3849B0" section-type="subsequent-section"><enum>102.</enum><header>Strengthening lupus
			 epidemiology; lupus study</header><text display-inline="no-display-inline">Part
			 B of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/243">42 U.S.C. 243 et seq.</external-xref>) is amended by
			 inserting after section 318B the following:</text>
				<quoted-block act-name="" display-inline="no-display-inline" id="HAD26C874A6BF4077ADA081FB92DF1881" style="traditional">
					<section commented="no" display-inline="no-display-inline" id="H908AEEF2835642BE836964652386C1E6" section-type="subsequent-section"><enum>318C.</enum><header>Strengthening lupus epidemiology</header><subsection commented="no" display-inline="yes-display-inline" id="HB59EBDC629DA4C46A185FCAD8BE4A3F1"><enum>(a)</enum><header>In
				general</header><text display-inline="yes-display-inline">The Secretary, acting
				through the Director of the Centers for Disease Control and Prevention, shall
				work with a consortium of leading United States academic health institutions
				that have expertise in the epidemiology of lupus to undertake a national scale
				lupus epidemiological study to determine the true prevalence and incidence of
				lupus in the United States.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="HAD27E0A0591849E7AC25ECCD84FD427B"><enum>(b)</enum><header>Use of
				funds</header><text display-inline="yes-display-inline">The Director of the
				Centers for Disease Control and Prevention shall enter into a cooperative
				agreement with the consortium described in subsection (a) to develop,
				implement, and manage a system for lupus data collection and analysis,
				including—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="H12FBC1AABF3C460081ADD0690A7C4BA"><enum>(1)</enum><text display-inline="yes-display-inline">the creation and use of a common data entry
				and management system across all study sites; and</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H846133BEA8C646AFB11B3003465197EE"><enum>(2)</enum><text display-inline="yes-display-inline">the enhancement of the 2 study sites
				involved in the existing lupus patient registry of the Centers for Disease
				Control and Prevention on the day before the date of enactment of the
				<short-title>Lupus Research, Education, Awareness,
				Communication, and Healthcare Amendments of 2007</short-title>.</text>
							</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H85D960CA51CF46DAB75DA7EB1FAB023"><enum>(c)</enum><header>Geographic
				representation</header><text display-inline="yes-display-inline">The Director
				of the Centers for Disease Control and Prevention shall ensure that the
				consortium described in subsection (a) represents different geographic regions
				of the United States that have a sufficient number of individuals of all racial
				and ethnic backgrounds disproportionately affected by lupus, including
				Hispanics, Asians, Native Americans, and African-Americans.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="HD537DAA287CB4FAE989B15A1F88EAD25"><enum>(d)</enum><header>Certain
				activities</header><text display-inline="yes-display-inline">In carrying out
				subsections (a) and (b), the consortium described in subsection (a) shall
				capture data related to all affected populations on all forms of lupus,
				including lupus related disorders.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="H6C26A3530717488595BAB5952823A8C4"><enum>(e)</enum><header>Authorization of
				appropriations</header><text display-inline="yes-display-inline">There are
				authorized to be appropriated to carry out this section $3,500,000 for each of
				the fiscal years 2008, 2009, 2010, and 2011.</text>
						</subsection></section><section commented="no" display-inline="no-display-inline" id="H8EEADDEF799F479BA18B051C18CBE84D" section-type="subsequent-section"><enum>318D.</enum><header>Lupus study and report by the Institute
		  of Medicine</header><subsection commented="no" display-inline="yes-display-inline" id="H74F155ABCB4646F5957462F000044D2"><enum>(a)</enum><header>Contract</header><text display-inline="yes-display-inline">The Secretary shall enter into a contract
				with the Institute of Medicine to conduct a study—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="H6DC83B700CE8482D899223313F083B74"><enum>(1)</enum><text display-inline="yes-display-inline">to evaluate the Federal and State
				activities related to lupus research, education, and awareness programs and
				activities and make recommendations for ways in which these initiatives could
				be expanded;</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H39DCFB28A4194E83A80090C9674139A9"><enum>(2)</enum><text display-inline="yes-display-inline">to identify the gaps in Federal research
				related to—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="H8930AADF99424085B194E40931E9DFF6"><enum>(A)</enum><text display-inline="yes-display-inline">the causes of lupus;</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC68B619821C3434E9ECD6F71EE8611C5"><enum>(B)</enum><text display-inline="yes-display-inline">lupus detection and diagnosis;</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H994CF80B6C0142FCBFC1DC167800C1E1"><enum>(C)</enum><text display-inline="yes-display-inline">lupus treatment; and</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H91BB485912F64B2595F98BD124AB001E"><enum>(D)</enum><text display-inline="yes-display-inline">lupus quality-of-life concerns;</text>
								</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HA01FD0C155424F509C543461097183C4"><enum>(3)</enum><text display-inline="yes-display-inline">to make recommendations for building and
				supporting the lupus research enterprise, including recommendations for
				strategies for future basic, clinical, social, and behavioral research—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="H4822D387B5954B4B89211667F2683DDE"><enum>(A)</enum><text display-inline="yes-display-inline">to determine the pathophysiology and
				pathogenesis of the disease; and</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H9208E772C20747A7A66C1F94FFEFD441"><enum>(B)</enum><text display-inline="yes-display-inline">to secure the development of new and
				improved lupus therapies and ways to diagnose the disease;</text>
								</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H460DBD7A4243407B9DDFFFBB6D046895"><enum>(4)</enum><text display-inline="yes-display-inline">to determine the gaps in lupus health
				professional education programs and public awareness efforts and make
				recommendations for ways in which the Federal Government can—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="H6D89A19932A34029AB6670008DDE231D"><enum>(A)</enum><text display-inline="yes-display-inline">improve public and health professional
				awareness of lupus; and</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H34ACE50F1A72446DA461DF00AB297814"><enum>(B)</enum><text display-inline="yes-display-inline">partner and support nonprofit voluntary
				health agencies (such as the Lupus Foundation of America, Inc.) and academic
				institutions and other interested stakeholders whose primary purposes are to
				increase public awareness of lupus and to improve the diagnosis and treatment
				of lupus;</text>
								</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H3AC16F846CE74B48A55BA4382CE55DA7"><enum>(5)</enum><text display-inline="yes-display-inline">to make recommendations regarding ways to
				improve the quality of life for people with lupus;</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HB036B12A07A64E279FEABEBD71623FC4"><enum>(6)</enum><text display-inline="yes-display-inline">to summarize the clinical and biological
				features of lupus and the characteristics and management of major symptoms and
				make recommendations for disease management and measurement; and</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H1DBF9C036A564A2CB587D9AF34CDC405"><enum>(7)</enum><text display-inline="yes-display-inline">to make recommendations for epidemiological
				studies in the various population groups affected by lupus in the United
				States.</text>
							</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HE5AF34DB915C4D80A0772B3FF8523111"><enum>(b)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 18 months after the date of
				enactment of the <short-title>Lupus Research, Education,
				Awareness, Communication, and Healthcare Amendments of 2007</short-title>, the
				Institute of Medicine shall submit to the Secretary a report containing the
				information described in paragraphs (1) through (7) of subsection
				(a).</text>
						</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section></title><title commented="no" id="HBD1F4C336A8F4EF89D112070F6B85BD" style="OLC"><enum>II</enum><header>Enhancing lupus awareness and
			 education</header>
			<section commented="no" display-inline="no-display-inline" id="H33D7BFC98342468C8052DC05DC2FBE86" section-type="subsequent-section"><enum>201.</enum><header>Increasing public
			 awareness and improving health professional education</header><text display-inline="no-display-inline">Part B of title III of the Public Health
			 Service Act (as amended by section 102) (<external-xref legal-doc="usc" parsable-cite="usc/42/243">42 U.S.C. 243 et seq.</external-xref>) is further
			 amended by inserting after section 318D the following:</text>
				<quoted-block act-name="" display-inline="no-display-inline" id="H897DA1333FDC4D5299EB0170C46DBFE2" style="traditional">
					<section commented="no" display-inline="no-display-inline" id="H7B40A455C2A64CD4A97C8FC392D00066" section-type="subsequent-section"><enum>318E.</enum><header>Increasing public awareness of lupus and improving health
		  professional education</header><subsection commented="no" display-inline="yes-display-inline" id="H1F419C2EBCD542AFB1E673C202696B0"><enum>(a)</enum><header>In
				general</header><text display-inline="yes-display-inline">The Secretary, acting
				through the Director of the Office on Women’s Health and in collaboration with
				the Lupus Foundation of America, Inc. and the National Center on Minority
				Health and Health Disparities of the National Institutes of Health, shall
				conduct and support a sustained national lupus public awareness and health
				professional education campaign, with an emphasis on reaching populations at
				highest risk for the disease.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="HA39DBA638D9B4AC888D3CEBA82D5892F"><enum>(b)</enum><header>Use of
				funds</header><text display-inline="yes-display-inline">In conducting the
				sustained national lupus public awareness and health professional educational
				campaign, the Director of the Office on Women’s Health shall—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="HC5036F5544ED4616B52414C1A736C9C"><enum>(1)</enum><text display-inline="yes-display-inline">promote increased awareness of early
				intervention and treatment so as to significantly improve the diagnosis,
				treatment, and quality of life for people with lupus;</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H6D0B0D5C23B7494CA3DB517E00E19438"><enum>(2)</enum><text display-inline="yes-display-inline">direct communication and education efforts
				toward minority communities that may be underserved or disproportionately
				affected by lupus; and</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H3FB3D2892F3344DCA933102637285319"><enum>(3)</enum><text display-inline="yes-display-inline">target at-risk women and health
				professionals likely to see women with lupus, including primary care physicians
				and specialists such as rheumatologists, nephrologists, dermatologists, and
				immunologists, so as to help reduce the amount of time taken to achieve a
				correct diagnosis of lupus.</text>
							</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HADCC0D464161461BB2D8C5217D86CB7E"><enum>(c)</enum><header>Certain
				activities</header><text display-inline="yes-display-inline">To the extent
				practicable and appropriate, the Secretary shall ensure that communications
				under subsections (a) and (b) provide the latest medically sound information
				related to the signs, symptoms, diagnosis, and disease management of
				lupus.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="HBF071FB8DB724D4F83399BE466D86B54"><enum>(d)</enum><header>Integration with
				other programs</header><text display-inline="yes-display-inline">To the extent
				practicable and appropriate, the Secretary shall integrate efforts under this
				section with other programs carried out by the Secretary.</text>
						</subsection><subsection commented="no" display-inline="no-display-inline" id="H1C91EF0EDB8D43359FD737B89487B06"><enum>(e)</enum><header>Authorization of
				appropriations</header><text display-inline="yes-display-inline">There are
				authorized to be appropriated to carry out this section $1,000,000 for each of
				the fiscal years 2008 through
				2012.</text>
						</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section></title></legis-body>
</bill>
